Table 1.
Patient characteristics and cross-sectional comparison of ALD and HCV cohorts.
| Parameter | ALD (n = 191) | HCV (n = 220) | p value⁎ |
|---|---|---|---|
| Age (years) | 55.3 ± 10.1 | 50.7 ± 11.1 | 0.0016 |
| Gender (male) | 73% | 63% | 0.14 |
| BMI (kg/m2) | 26.2 ± 4.3 | 24.1 ± 4.0 | 0.0016 |
| DM (present) | 22% | 27% | 0.3120 |
| Bilirubin total (mg/dl) | 1.1 (0.5-1.7) | 0.7 (0.5-0.9) | ≪0.0001 |
| AST (U/L) | 46 (32-75) | 45 (29-68) | ≪0.0001 |
| ALT (U/L) | 35 (22-51) | 46 (29-68) | ≪0.05 |
| Hemoglobin (g/dl) | 10.7 ± 3.2 | 13.4 ± 2.0 | ≪0.0001 |
| Leucocytes (103/μl) | 7.3 ± 2.9 | 7.5 ± 6.8 | 0.5436 |
| Platelets (103/μl) | 194 ± 85 | 172 ± 80 | 0.095 |
| INR | 1.2 ± 0.39 | 1.1 ± 0.12 | 0.048 |
| Creatinine (mg/dl) | 0.60 ± 0.37 | 0.87 ± 0.65 | 0.0068 |
| APRI | 2.1 ± 1.2 | 1.8 ± 1.1 | 0.0188 |
| Liver size (cm) | 16.1 ± 2.9 | 14.3 ± 1.6 | ≪0.0001 |
| Spleen size (cm) | 11.9 ± 2.9 | 15.6 ± 3.6 | ≪0.0001 |
| Liver stiffness (kPa) | 31.0 ± 25.2 | 14.9 ± 10.3 | ≪0.001 |
| CAP (dB/m) | 285 ± 67 | 298 ± 49 | 0.2692 |
| Spleen stiffness (kPa) | 32.6 ± 21.7 | 42.0 ± 16.6 | ≪0.0001 |
| SL/LS ratio | 0.86 ± 0.79 | 1.46 ± 0.83 | ≪0.0001 |
| SS/LS ratio | 1.72 ± 1.31 | 3.8 ± 3.08 | ≪0.0001 |
| Fibrosis stages (non-invasive) | 0.0028 | ||
| F0 | 13.6% | 15.0% | |
| F1-2 | 22.2% | 30.0% | |
| F3 | 8.5% | 16.8% | |
| F4 | 55.7% | 38.2% | |
ALD, alcohol-related liver disease; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; DM, diabetes mellitus; HCV, hepatitis C virus; INR, international normalized ratio; LS, liver stiffness; SS, spleen stiffness.
*
The statistical test used is unpaired t test.